B
66.16
-0.35 (-0.53%)
| Previous Close | 66.51 |
| Open | 66.05 |
| Volume | 3,317,017 |
| Avg. Volume (3M) | 1,726,274 |
| Market Cap | 12,608,972,800 |
| Price / Earnings (TTM) | 39.86 |
| Price / Earnings (Forward) | 16.84 |
| Price / Sales | 4.55 |
| Price / Book | 2.29 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | 11.71% |
| Operating Margin (TTM) | 15.27% |
| Diluted EPS (TTM) | 1.66 |
| Quarterly Revenue Growth (YOY) | 28.30% |
| Quarterly Earnings Growth (YOY) | 162.70% |
| Total Debt/Equity (MRQ) | 11.13% |
| Current Ratio (MRQ) | 4.27 |
| Operating Cash Flow (TTM) | 414.70 M |
| Levered Free Cash Flow (TTM) | 144.67 M |
| Return on Assets (TTM) | 3.00% |
| Return on Equity (TTM) | 6.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | BioMarin Pharmaceutical Inc. | Bearish | Bearish |
AIStockmoo Score
0.4
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.38 |
|
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.87% |
| % Held by Institutions | 97.63% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 109.00 (JP Morgan, 64.75%) | Buy |
| Median | 86.00 (29.99%) | |
| Low | 65.00 (Baird, -1.75%) | Hold |
| Average | 89.09 (34.66%) | |
| Total | 7 Buy, 4 Hold | |
| Avg. Price @ Call | 66.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 12 Dec 2024 | 90.00 (36.03%) | Buy | 66.26 |
| 30 Oct 2024 | 90.00 (36.03%) | Buy | 66.68 | |
| Wolfe Research | 15 Nov 2024 | 95.00 (43.59%) | Buy | 63.42 |
| Baird | 30 Oct 2024 | 65.00 (-1.75%) | Hold | 66.68 |
| Canaccord Genuity | 30 Oct 2024 | 84.00 (26.96%) | Hold | 66.68 |
| Citigroup | 30 Oct 2024 | 81.00 (22.43%) | Hold | 66.68 |
| Evercore ISI Group | 30 Oct 2024 | 105.00 (58.71%) | Buy | 66.68 |
| JP Morgan | 30 Oct 2024 | 109.00 (64.75%) | Buy | 66.68 |
| RBC Capital | 30 Oct 2024 | 80.00 (20.92%) | Hold | 66.68 |
| 04 Oct 2024 | 80.00 (20.92%) | Hold | 69.51 | |
| UBS | 30 Oct 2024 | 106.00 (60.22%) | Buy | 66.68 |
| Raymond James | 10 Oct 2024 | 79.00 (19.41%) | Buy | 69.85 |
| Barclays | 04 Oct 2024 | 86.00 (29.99%) | Buy | 69.51 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |